675 articles in this topic
A Cambridge-developed AI-engineered vaccine protected against multiple coronaviruses in 39 volunteers, pointing toward pandemic-proof immunity.
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
A 260-organoid biobank reveals statins target chemoresistant pancreatic cancer by disrupting cholesterol and glycosylation pathways.
Leukemic stem cells produce their own ketone bodies to block ferroptosis, revealing a metabolic weak point that could be targeted therapeutically.
A phase II trial tests ipilimumab and nivolumab paired with immunoembolization against liver-spread uveal melanoma.
A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.
Researchers mapped distinct cell populations in human pancreatic ducts, finding two subtypes that drive aggressive, lower-survival pancreatic cancer.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
MD Anderson researchers evaluated vemurafenib, cetuximab, and irinotecan together to find the optimal dose and safety profile for advanced solid tumors.
Swiss researchers completed a 74-patient phase 2 trial exploring optimal dosing schedules for dual checkpoint blockade in metastatic renal cell carcinoma.
A phase 1 trial finds intraventricular nivolumab is safe for leptomeningeal metastases, with median survival of 6.6 months.
